Skip to main content

Table 4 Governments in the WHO European region reporting activities addressing viral hepatitis by WHO Global Hepatitis Programme strategic axis and EU/EFTA membership (N=44)

From: Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey

  

Non EU/EFTA n=16 (%)

EU/EFTA n=28 (%)

P-value

National coordination

Have viral hepatitis programme activities address PWID as a specific population

10 (63)

22 (79)

0.512

 

Have a written national viral hepatitis prevention & control strategy which also targets ID use

6 (38)

6 (21)

0.335

Axis 1

Held events for World Hepatitis Day 2012

7 (44)

10 (36)

0.765

 

Funded viral hepatitis awareness campaigns focusing on harm reduction for PWID (other than World Hepatitis Day)

5 (31)

5 (18)

0.404

Axis 2

Conduct regular serosurveys among PWID

6 (38)

6 (21)

0.639

Axis 3

Have a national policy for prevention & control of viral hepatitis among PWID

9 (56)

16 (57)

0.954

Axis 4

Have HBV & HCV testing which is:

   
 

• Free of charge for all

6 (38)

14 (50)

0.569

 

• Free of charge for PWID

2 (13)

4 (14)

0.423

 

Have publicly funded treatment for HBV

9 (56)

27 (96)

0.004*

 

HBV Drugs on national essential medicines list or subsidized by government:

   
 

• Interferon alpha

12 (75)

22 (79)

0.786

 

• Pegylated interferon

11 (69)

22 (79)

0.469

 

• Lamivudine

13 (81)

24 (86)

0.697

 

• Adefovir dipivoxil

4 (25)

20 (71)

0.003*

 

• Entecavir

3 (20)

19 (68)

0.002*

 

• Telbivudine

4 (25)

13 (46)

0.160

 

• Tenofovir

8 (50)

19 (68)

0.242

 

Have publicly funded treatment for HCV

9 (56)

26 (93)

0.010*

 

HCV Drugs on national essential medicines list or subsidized by government:

   
 

• Interferon alpha

8 (50)

22 (79)

0.050*

 

• Pegylated interferon

12 (75)

23 (82)

0.572

 

• Ribavirin

14 (88)

24 (86)

0.868

 

• Boceprevir

2 (13)

15 (54)

0.007*

 

• Telaprevir

3 (19)

14 (50)

0.041*